Inhibrx, Inc. (INBX) financial statements (2022 and earlier)

Company profile

Business Address 11025 N. TORREY PINES ROAD, SUITE 200
LA JOLLA, CA 92037
State of Incorp. CA
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments131,301128,664
Cash and cash equivalents131,301128,664
Receivables878615
Prepaid expense6,3432,204
Other current assets590689
Total current assets:139,112132,172
Noncurrent Assets
Operating lease, right-of-use asset6,3387,831
Property, plant and equipment3,1533,492
Other noncurrent assets1,847245
Total noncurrent assets:11,33811,568
TOTAL ASSETS:150,450143,740
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities18,74626,815
Accounts payable9,12513,458
Accrued liabilities9,62113,357
Deferred revenue2,0343,081
Other undisclosed current liabilities1,6741,503
Total current liabilities:22,45431,399
Noncurrent Liabilities
Long-term debt and lease obligation75,50335,951
Long-term debt, excluding current maturities70,47029,244
Operating lease, liability5,0336,707
Liabilities, other than long-term debt110917
Deferred revenue110737
Other liabilities 180
Total noncurrent liabilities:75,61336,868
Total liabilities:98,06768,267
Stockholders' equity
Stockholders' equity attributable to parent52,38375,473
Common stock44
Additional paid in capital279,526220,848
Accumulated deficit(227,147)(145,379)
Total stockholders' equity:52,38375,473
TOTAL LIABILITIES AND EQUITY:150,450143,740

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
Revenues7,23112,888
Gross profit:7,23112,888
Operating expenses(83,795)(80,331)
Operating loss:(76,564)(67,443)
Nonoperating expense(5,202)(8,191)
Loss from continuing operations before equity method investments, income taxes:(81,766)(75,634)
Loss from equity method investments (487)
Loss from continuing operations before income taxes:(81,766)(76,121)
Income tax expense(2)(3)
Net loss available to common stockholders, diluted:(81,768)(76,124)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
Net loss:(81,768)(76,124)
Comprehensive loss, net of tax, attributable to parent:(81,768)(76,124)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: